8-K: Interpace Biosciences Reports Strong Q3 2025 Thyroid Results

Interpace Biosciences announced its third quarter 2025 financial results, highlighting record thyroid test volumes and revenue, alongside improved cash collections and operational efficiencies.

Summary

• Net Revenue for Q3 2025 was $8.8 million, a 29% decrease from $12.3 million in Q3 2024 (GAAP) but a 22% increase from $7.3 million on a Pro Forma basis (thyroid-only business).
• Income from continuing operations in Q3 2025 was $1.0 million, compared to $1.8 million in Q3 2024 (GAAP) and a loss of $0.7 million on a Pro Forma basis in Q3 2024.
• Thyroid test volume increased by 12% year-over-year to record levels in Q3 2025.
• Thyroid revenue reached $8.8 million in Q3 2025, up 22% year-over-year to record levels on a Pro Forma basis.
• Cash collections for Q3 2025 totaled $10.0 million, compared to $11.2 million in Q3 2024 (GAAP) and $7.5 million on a Pro Forma basis in Q3 2024.
• Average revenue per test increased by 5%, and days sales outstanding were reduced by 22%.
• The third quarter of 2025 marked the first full quarter operating as a Thyroid-only diagnostics testing company, following the discontinuation of PancraGEN in May 2025.
• Adjusted EBITDA for Q3 2025 was $1.3 million, compared to $2.5 million in Q3 2024 (GAAP) and $0.1 million on a Pro Forma basis in Q3 2024.

Sentiment

Score: 7

Explanation: The company demonstrated strong growth and operational improvements in its core thyroid diagnostics business, achieving record volumes and revenue in this focused segment. Enhanced cash collections and strategic investments contribute to a positive outlook for the refined business model. However, the overall GAAP revenue and profit decline due to the strategic discontinuation of PancraGEN and existing risks related to financing and reimbursement temper the sentiment slightly.

Positives

• Record thyroid test volumes, up 12% year-over-year.
• Record thyroid revenue of $8.8 million, up 22% year-over-year on a Pro Forma basis, demonstrating strong performance in the focused segment.
• Strong cash collections of $10.0 million in Q3 2025.
• Average revenue per test increased by 5%, indicating improved reimbursement and pricing strategies.
• Days sales outstanding reduced by 22%, reflecting enhanced collection initiatives.
• Strategic investments in laboratory operational efficiency, leveraging AI and automation, are expected to drive future improvements.
• Strengthened balance sheet through additional principal payments on long-term debt.
• Income from continuing operations of $1.0 million in Q3 2025, a significant improvement from a Pro Forma loss of $0.7 million in the prior year quarter.

Negatives

• Total Net Revenue decreased by 29% from $12.3 million in Q3 2024 (GAAP) to $8.8 million in Q3 2025, primarily due to the discontinuation of the PancraGEN product.
• Gross Profit percentage decreased to 62% in Q3 2025 from 64% in the prior year quarter (GAAP).
• Operating income decreased to $1.1 million in Q3 2025 from $2.3 million in the prior year quarter (GAAP).
• Income from continuing operations decreased to $1.0 million in Q3 2025 from $1.8 million in the prior year quarter (GAAP).
• Adjusted EBITDA decreased to $1.3 million in Q3 2025 from $2.5 million in the prior year quarter (GAAP).
• Cash collections decreased to $10.0 million in Q3 2025 from $11.2 million in the prior year quarter (GAAP).
• Loss from discontinued operations, net of tax, was $0.1 million in Q3 2025.

Risks

• Estimates of future revenue and cash flows, as well as Pro Forma financial results and adjusted EBITDA, may prove to be materially inaccurate.
• The company has a prior history of operating losses.
• The company's ability to adequately finance its business and seek alternative sources of financing is a concern.
• The company's ability to repay borrowings from BroadOak.
• Dependence on sales and reimbursements from its clinical services.
• The company's ability to retain or secure reimbursement, including reliance on third parties to process and transmit claims to payers, and the adverse impact of any delay, data loss, or other disruption in processing or transmitting such claims.
• Revenue recognition is based in part on estimates for future collections, which estimates may prove to be incorrect.
• The company's ability to continue to restructure itself in light of the loss of reimbursement for its PancraGEN product.

Future Outlook

The company expects continued growth in revenue, profitability, and cash flow as a Thyroid-only clinical diagnostics business. Management believes their unique combination testing platform, ThyGeNEXT and ThyraMIRv2, delivers high performance and convenience, supporting physicians in making confident and informed patient-management decisions.

Management Comments

• "Our continued focus on reimbursement improvements resulted in a 5% increase in average revenue per test and a 22% reduction in days sales outstanding." Chris McCarthy, CFO.
• "Our strong cash position supported strategic investments in laboratory operational efficiency, leveraging AI and automation as part of our digital strategy. These initiatives also enabled us to strengthen our balance sheet through additional principal payments on our long-term debt." Chris McCarthy, CFO.
• "The third quarter represented the first full quarter of the Company being a Thyroid-only diagnostics testing company." Tom Burnell, President and CEO.
• "We are excited about the Company's continued growth in revenue, profitability and cash flow as a Thyroid-only clinical diagnostics business." Tom Burnell, President and CEO.
• "We believe our unique combination testing platform delivers the confidence of high performance with the convenience of simple specimen handling." Tom Burnell, President and CEO.

Industry Context

Interpace Biosciences is strategically focusing on personalized medicine within the thyroid diagnostics sector. The emphasis on leveraging AI and automation for operational efficiency aligns with broader industry trends towards technological integration to enhance diagnostic accuracy, reduce costs, and improve patient outcomes. The shift to a 'Thyroid-only' model indicates a specialized market approach, aiming to capitalize on their proprietary ThyGeNEXT and ThyraMIRv2 tests to gain a competitive edge.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders: Potential for increased value due to focused growth, improved profitability, and operational efficiency in the core thyroid diagnostics business. However, existing risks related to financing and reimbursement should be monitored.
• Employees: The focus on AI and automation may lead to shifts in skill requirements and potential for growth in specialized areas within the company.
• Customers (Physicians/Patients): Continued access to specialized molecular diagnostic tests (ThyGeNEXT, ThyraMIRv2) for thyroid cancer diagnosis and management, with potential for improved service delivery through efficiency gains.
• Creditors (BroadOak): Additional principal payments on long-term debt indicate improved financial health and a commitment to debt repayment, which is positive for creditors.

Next Steps

• Continue to drive growth in revenue, profitability, and cash flow as a Thyroid-only clinical diagnostics business.
• Further leverage AI and automation to enhance laboratory operational efficiency.
• Continue strengthening the balance sheet through additional principal payments on long-term debt.

Key Dates

Recommendation

While Interpace Biosciences shows promising growth and operational improvements in its newly focused thyroid diagnostics segment, evidenced by record volumes and revenue, the overall GAAP financial metrics (revenue, gross profit, operating income, EBITDA) have declined year-over-year due to the strategic divestiture of PancraGEN. The company has a history of operating losses and faces ongoing risks related to financing, reimbursement, and reliance on estimates for future collections. The strategic pivot is positive, but sustained performance and mitigation of identified risks need further observation before a stronger recommendation can be made.

Keywords

Interpace Biosciences, IDXG, Thyroid diagnostics, molecular diagnostics, ThyGeNEXT, ThyraMIRv2, Q3 2025 earnings, financial results, clinical diagnostics, personalized medicine, cancer diagnosis, SEC filing